Výsledky vyhledávání

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

Autor: Francis Y.F. Lee, Feng R. Luo, Stephen Castaneda, Robert A. Wild, David Kan, Tai W. Wong, Zheng Yang, Robert A. Kramer, Kelly McGlinchey, Ivan Inigo, Christine Flefleh, Amy Camuso, Krista Fager, Huijin Dong

Publikováno v: Clinical Cancer Research. 11:5558-5565

Purpose: Epidermal growth factor receptor (EGFR), a protein tyrosine kinase expressed in many types of human cancers, has been strongly associated with tumor progression. Cetuximab is an IgG1 anti-EGFR chimeric mouse/human monoclonal antibody that ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc1519747d31c294828e06b97e44c12
https://doi.org/10.1158/1078-0432.ccr-05-0368

Zobrazit plný text záznamu

Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor

Publikováno v: Cancer Research. 65:3781-3787

The insulin-like growth factor I receptor (IGF-IR) is a transmembrane tyrosine kinase that is essential to growth and development and also thought to provide a survival signal for the maintenance of the transformed phenotype. There has been increasin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75c86c8d67f12be593606f26753f4d4c
https://doi.org/10.1158/0008-5472.can-04-4602

Zobrazit plný text záznamu

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor

Autor: Feng Roger Luo, Robert A. Wild, Anne Blackwood-Chirchir, Francis Y. Lee, Holly Palme, Yu Chen Barrett, Amy Camuso, Richard Smykla, Zheng Yang, Susan Galbraith, Krista Fager, Mei-Li Wen, Kelly McGlinchey

Publikováno v: Cancer chemotherapy and pharmacology. 62(6)

Dasatinib (BMS-354825) is a potent, oral multi-targeted kinase inhibitor. It is an effective therapy for patients with imatinib-resistant or -intolerant Ph+ leukemias,. It has demonstrated promising preclinical anti-tumor activity, and is under clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79448555c9793d95601df5fba937a33d
https://pubmed.ncbi.nlm.nih.gov/18301894

Zobrazit plný text záznamu

Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Publikováno v: Bioorganicmedicinal chemistry letters. 15(7)

Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9c76933b8d588ad80d95bacaf16d2ea
https://pubmed.ncbi.nlm.nih.gov/15780629

Zobrazit plný text záznamu

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

Autor: Robert A. Wild, Ivan Inigo, Amy Camuso, Kelly McGlinchey, Frank Lee, Robert Kramer, Feng Roger Luo, Zheng Yang, Stephen Castaneda, Krista Fager, H. Dong, William C. Rose, Christine Flefleh, David Kan

Publikováno v: Cancer chemotherapy and pharmacology. 56(5)

Purpose: The epidermal growth factor receptor (EGFR), a protein tyrosine kinase expressed in many types of human cancers including colon and breast, has been strongly associated with tumor progression. Cetuximab, an IgG1 anti-EGFR chimeric mouse/huma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca703cd6ba6b501199652439e0dfcf70
https://pubmed.ncbi.nlm.nih.gov/15947929

Zobrazit plný text záznamu

Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts

Autor: Stephen Castenada, I. Ingio, Kelly McGlinchey, Krista Menard, Amy Camuso, Frank Lee, Christine Flefleh, William C. Rose, David Kan

Publikováno v: Journal of Clinical Oncology. 24:12017-12017

12017 Background: Ixabepilone belongs to a class of structurally novel, microtubule-stabilizing agents that exert their antimitotic action by binding to tubulin with a binding mode that is distinct from the taxanes. Preclinical findings that ixabepil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e7dcdf7466cb258d6355a97a95e9e12
https://doi.org/10.1200/jco.2006.24.18_suppl.12017

Zobrazit plný text záznamu

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML)

Autor: Stephen Castenada, Richard Smykla, David Kan, Roger Luo, Kelly McGlinchey, Christine Flefleh, Rajeev S. Bhide, Louis J. Lombardo, Francis Y. Lee, Krista Fager, Ivan Inigo, Robert M. Borzilleri, Mei-Li Wen, Amy Camuso, Robert A. Wild

Publikováno v: Blood. 106:1994-1994

Resistance to imatinib is a growing concern in CML, particularly in advanced disease. The most common cause of resistance is mutations in BCR-ABL, but other mechanisms have also been identified, including over-expression of BCR-ABL, activation of SRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f1ab0d871564b054b07391c8aeeb6b4
https://doi.org/10.1182/blood.v106.11.1994.1994

Zobrazit plný text záznamu

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth

Autor: Louis J. Lombardo, Richard Smykla, Mei-Li Wen, Feng Roger Luo, Krista Fager, Kelly McGlinchey, Amy Camuso, David Kan, Robert M. Borzilleri, Stephen Castaneda, Francis Y. Lee, Ivan Inigo, Robert Kramer, Robert A. Wild, Christine Flefleh

Publikováno v: Blood. 104:1988-1988

Chronic myeloid leukemia (CML) is a stem cell disorder caused by a constitutively activated tyrosine kinase, the BCR-ABL oncoprotein. Imatinib (STI571, Gleevec) is a small-molecule inhibitor of this kinase that produces clinical remissions in CML pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::297f5b813272a8e3ea734cdf2a47915f
https://doi.org/10.1182/blood.v104.11.1988.1988

Zobrazit plný text záznamu

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825

Autor: Francis Y. Lee, David Kan, Kelly McGlinchey, Richard Smykla, Amy Camuso, Louis J. Lombardo, Zheng Yang, Feng Roger Luo, Ivan Inigo, Christine Flefleh, Mei-Li Wen, Robert A. Wild, Stephen Castenada, Robert Kramer, Krista Fager, Robert M. Borzilleri

Publikováno v: Blood. 104:1987-1987

Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) originates from multipotential stem cells and is caused by a reciprocal translocation between chromosomes 9 and 22, resulting in the formation of the fusion protein BCR-ABL, a cons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c7defcee06f39219a2b46942a5ede026
https://doi.org/10.1182/blood.v104.11.1987.1987

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání